Work

PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps9146

Authors: Mark A. Socinski, Kai He, Tianhong Li, Dan Chen, Kun He, Yang Liu, Pan Zheng

Institutions: AdventHealth Orlando, AdventHealth, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, UC Davis Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379282679

Cites:

Cited by: 3

Related to: 10